Literature DB >> 22805865

Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience.

John C Bell1, Barnaby G Rylah, Robert W Chambers, Helen Peet, Faheez Mohamed, Brendan J Moran.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) is an established treatment for patients with pseudomyxoma peritonei. There is now increasing evidence for the use of CRS and HIPEC in the treatment of other peritoneal surface malignancies. There is currently no consensus on the perioperative management of this patient group.
METHODS: An international survey of practice was conducted using an online survey tool. Centers were identified from the list of delegates attending the Seventh International Workshop on Peritoneal Surface malignancy held in Uppsala, Sweden, in September 2010.
RESULTS: Fully completed surveys were received from 29 of 41 identified centers (71 %). The survey covers the combined experience amassed by anesthesiologists caring for 8,467 patients undergoing cytoreductive surgery. Intraoperative fluid management, management of coagulopathy, management of the HIPEC phase of the operation, and postoperative analgesia caused the greatest difficulties for the anesthesia team with variation in management identified between different institutions. The incidence of epidural abscess in this patient group was found to be 1:2,139.
CONCLUSIONS: Optimal preoperative, intraoperative, and postoperative care is crucial to diminish the complications in this complex treatment strategy. Multicenter collaboration is suggested to gain evidence on the best strategies for perioperative management. Further data collection needs to be undertaken to assess the safety of epidural anesthesia in this patient group.

Entities:  

Mesh:

Year:  2012        PMID: 22805865     DOI: 10.1245/s10434-012-2496-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Reply to authors' letter for the manuscript entitled: "goal-directed therapy for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: the right approach in the right place".

Authors:  Claudia Claroni; Giulia Torregiani; Marco Covotta; Ester Forastiere
Journal:  J Gastrointest Surg       Date:  2015-04-23       Impact factor: 3.452

2.  Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy.

Authors:  Toshiyuki Kitai; Kenya Yamanaka; Yuya Miyauchi; Masahiro Kawashima
Journal:  Int J Clin Oncol       Date:  2017-01-04       Impact factor: 3.402

3.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

4.  Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.

Authors:  Doralina L Anghelescu; Christina-Lin Brown; Andrew J Murphy; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Zachary E Stiles; Michael W Bishop; Luke Douthitt; Jeremiah L Deneve
Journal:  Ann Surg Oncol       Date:  2018-10-23       Impact factor: 5.344

5.  Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement.

Authors:  Harveshp D Mogal; Edward A Levine; Nora F Fino; Chukwuemeka Obiora; Perry Shen; John H Stewart; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2015-11-16       Impact factor: 5.344

Review 6.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  S Durnford; L Boss; J Bell
Journal:  BJA Educ       Date:  2021-02-16

7.  Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study.

Authors:  Sven Van Poucke; Dana Huskens; Kurt Van der Speeten; Mark Roest; Bart Lauwereins; Ming-Hua Zheng; Seppe Dehaene; Joris Penders; Abraham Marcus; Marcus Lancé
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

8.  Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.

Authors:  Vincent Boudousq; Laure Bobyk; Muriel Busson; Véronique Garambois; Marta Jarlier; Paraskevi Charalambatou; André Pèlegrin; Salomé Paillas; Nicolas Chouin; François Quenet; Patrick Maquaire; Julien Torgue; Isabelle Navarro-Teulon; Jean-Pierre Pouget
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

9.  Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience.

Authors:  Marie-Elisabeth Kajdi; Beatrice Beck-Schimmer; Ulrike Held; Reto Kofmehl; Kuno Lehmann; Michael Thomas Ganter
Journal:  World J Surg Oncol       Date:  2014-05-01       Impact factor: 2.754

10.  Anaesthetic management and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective analysis.

Authors:  Kalpana P Balakrishnan; Sreedevi Survesan
Journal:  Indian J Anaesth       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.